Realm Therapeutics to initiate Phase II trial for allergic conjunctivitis

Realm Therapeutics is set to initiate a Phase II clinical trial of PR013 to treat allergic conjunctivitis (AC), following approval of its investigational new drug (IND) application by the US Food and Drug Administration (FDA).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news